Article Figures & Data
Tables
Variables n (%) Age, median year (minimum - maximum) 9 year (3-17.5) Age groups ≤5 years old 11 (21.2) 5-10 years old 17 (32.7) ≥10 years old 24 (46.1) Gender Male 25 (48.1) Female 27 (51.9) Nationality Turkish 50 (96.2) Refugee 2 (3.8) Symptom duration, median months (minimum - maximum) 1 month (1-24) Symptoms Lymphadenopathy 52 (100) Fever 16 (30.8) Weight loss 13 (25.0) Night sweats 10 (19.2) Pruritus 4 (7.7) B symptoms 22 (42.3) Other clinical features Bulk disease involvements 10 (19.2) Splenic 14 (26.9) Bone 5 (9.6) Pulmonary 4 (7.7) Bone marrow 2 (3.8) Liver 1 (1.9) Stage I 0 (0.0) II 22 (42.3) III 24 (46.2) IV 6 (11.5) Risk group Low 15 (28.8) Intermediate 16 (30.8) High 21 (40.4) Histologic variant Classical Hodgkin lymphoma Nodular sclerosis type 28 (53.8) Mixed cellularity type 18 (34.7) Lymphocyte rich type 1 (1.9) Lymphocyte depleted type 0 (0.0) Unclassified 5 (9.6) Chemotherapy regimens Adriamycin, bleomycin sulfate, vinblastine sulfate, and dacarbazine (ABVD) 17 (32.7) Oncovin, prednisone, procarbazine hydrochloride, and adriamycin (OPPA) or OEPA + COPP 14 (26.9) OPPA or oncovin, etoposide phosphate, prednisone, and adriamycin (OEPA) 7 (13.5) ABVD + cyclophosphamide, oncovin, procarbazine hydrochloride, and prednisone (COPP) 7 (13.5) ABVD + cyclophosphamide, oncovin, prednisone, and dacarbazine (COPDac) 6 (11.5) Adriamycin, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide 1 (1.9) Values are presented as a number and (%).
Parameters n (%) Hemoglobin levels, gr/dL, median (min-max)* 11.8 (7.1-14.2) Normal 33 (63.5) Anemia 19 (36.5) Leukocyte counts, mm3, median (min-max)* 9805 (3860-23260) Normal 37 (71.2) High 11 (21.2) Low 4 (7.6) Neutrophil counts, mm3, mean±SD 7230.8±4535.7 Normal 31 (59.6) High 20 (38.5) Low 1 (1.9) Lymphocyte counts,mm3, mean±SD 2319.1±1040.4 Normal 44 (84.6) Low 8 (15.4) Monocyte counts, mm3, mean±SD 718.7±341.2 Normal 32 (61.5) High 17 (32.7) Low 3 (5.8) Platelets counts, mm3, mean±SD 381326.9±133083.3 Normal 40 (76.9) High 11 (21.2) Low 1 (1.9) NLR, median (min-max)* 2.78 (0.46-56.5) ≤3.17 29 (55.8) >3.17 23 (44.2) PLR, median (min-max)* 156.3 (9.96-2235.0) ≤180 31 (59.6) >180 21 (40.4) MLR, median (min-max)* 0.3 (0.05-2.5) ≤0.29 22 (44.2) >0.29 30 (55.8) ↵* The distributions of these parameters were not normal. Values are presented as a number and (%). NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, MLR: Monocyte-to-lymphocyte ratio, gr/dL: grams/decilitre, min: minimum, max: maximum, SD: standard deviation
- Table 3
- The changes of lymphocyte count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratios according to clinical and laboratory features.
Clinical and laboratory features Lymphocyte counts (/mm3) Neutrophil-to-lymphocyte ratio Platelet-to-lymphocyte ratio Monocyte-to-lymphocyte ratio Median (min-max) P-values Median (min-max) P-values Median (min-max) P-values Median (min-max) P-values B symptoms, mean±SD Absent (n=30) 2490.8±927.4 0.167 2.11 (0.46-8.9) 0.003* 137.6 (76.7-425.0) 0.017* 0.29 (0.06-0.8) 0.005* Present (n=22) 2084.9±1158.3 4.67 (0.75-56.5) 218.3 (9.96-2235.0) 0.38 (0.05-2.5) Bulky disease Absent (n=42) 2320 (400-4920) 0.007* 2.5 (0.46-7.75) 0.002* 139.5 (9.96-812.5) 0.001* 0.3 (0.05-2.5) 0.057 Present (n=10) 1560 (200-5250) 7.46 (1.34-56.5) 343.6 (87.62-2235.0) 0.37 (0.21-1.5) Erythrocyte sedimentation rate, mean±SD ≤40 mm/h (n=27) 2429.0±1061.6 0.434 2.12 (0.46-56.5) 0.042* 140.9 (9.96-2235) 0.268* 0.29 (0.05-1.5) 0.043* >40 mm/h (n=25) 2200.4±1025.2 3.42 (0.75-8.0) 165.87 (77.39-812.5) 0.35 (0.12-2.5) Lactate dehydrogenase ≤2 x UNL (n=48) 2250 (200-5250) 0.655* 2.76 (0.46-56.5) 0.31* 152.3 (9.96-2235.0) 0.180* 0.3 (0.05-1.5) 0.216 >2 x UNL (n=4) 2250 (400-2780) 5.45 (1.15-8) 274.26 (130.74-812.5) 0.56 (0.23-2.5) Stage II (n=22) 2260 (1160-5250) 0.323* 2.62 (0.46-13.1) 0.166* 139.5 (9.96-343.6) 0.079* 0.29 (0.13-0.67) 0.064* III (n=24) 2200 (200-4080) 2.7 (0.57-56.5) 171.9 (76.7-2235.0) 0.3 (0.05-1.5) IV (n=6) 1800 (400-2900) 5.41 (2.1-8) 256.0 (109.3-812.5) 0.38 (0.27-2.5) Risk group Low (n=15) 2225 (1160-5250) 0.415* 1.85 (0.46-4.33) 0.117* 138.03 (87.62-258.62) 0.103* 0.25 (0.13-0.45) 0.043* Intermediate (n=16) 2350 (1000-4080) 2.88 (0.57-13.09) 173.53 (76.67-425.0) 0.3 (0.06-0.8) High (n=21) 2105 (200-4920) 3.42 (0.75-56.5) 171.86 (9.96-2235.0) 0.36 (0.05-2.5) Outcomes Alive (n=48) 2300 (1000-5250) 0.004* 2.65 (0.46-13.09) 0.017* 146.5 (9.96-523.1) 0.004* 0.3 (0.05-0.83) 0.008* Dead (n=4) 780 (200-1850) 6.82 (3.28-56.5) 543.0 (258.6-2235) 0.98 (0.37-2.5) ↵* Since the distribution of these variables was not normal, non-parametric tests were used. Also, median plus minimum-maximum values were given as descriptive statistics for these variables. UNL: upper normal limit, SD: standard deviation
Variables Overall survival Estimate SE P-values B symptoms Absent (n=30) 96.0 3.5 0.229 Present (n=22) 85.2 8 Bulky disease Absent (n=42) 94.9 3.5 0.088 Present (n=10) 71.1 18 Erythrocyte sedimentation rate ≤40 mm/h (n=27) 91.5 5.8 0.996 >40 mm/h (n=25) 90.4 6.6 Hemoglobin Normal (n=33) 92.2 5.2 0.632 Anemia (n=19) 89.2 7.2 Leukocyte counts Normal (n=37) 91.2 4.8 0.852 High (n=11) 87.5 11.7 Low (n=4)a Neutrophil counts Normal (n=31) 93.1 4.7 0.857 High (n=21) 87.2 8.6 Lymphocyte counts Normal (n=44) 96.7 3.7 <0.0001 Low (n=8) 60.0 18.2 Monocyte counts Normal (n=32) 89.0 6.1 0.842 High (n=17) 93.3 6.4 Low (n=3)a Platelet counts Normal (n=40) 91.9 4.5 0.96 High (n=11) 87.5 11.7 Low (n=1)a Neutrophil-to-lymphocyte ratio ≤3.17 (n=29) 100 - 0.018 >3.17 (n=23) 78.6 9.7 Platelet-to-lymphocyte ratio ≤180 (n=30) 100 - 0.009 >180 (n=22) 76.5 10.6 Monocyte-to-lymphocyte ratio ≤0.29 (n=23) 100 - 0.059 >0.29 (n=29) 83.1 7.9 Risk group Low (n=15) 92.9 6.9 0.895 Intermediate (n=16) 90.9 8.7 High (n=21) 90.2 6.6 ↵a Since the number of patients in this group was small, they were not included in this analysis. SE: standard error
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.